About us Pricing ContactSubscribe

P

Peter McLaughlin

The University of Texas MD Anderson Cancer CenterORCID https://orcid.org/0000-0002-8011-642X

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Journal of Clinical Oncology19982,755 citationsFirst authorCorresponding

Peter McLaughlin · Scinovex